✦ LIBER ✦

104. Randomized phase III study of the new selective aromatase inhibitor arimidex (A) (ZD1033) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer

✍ Scribed by A.U. Buzdar; P.V. Plourde; S.E. Jones; C.L. Voge; J.M. Wolters; P.D. Eisenberg

Book ID: 113404612
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 188 KB
Volume: 4
Category: Article
ISSN: 0960-9776
DOI: 10.1016/0960-9776(95)90196-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

3. A randomized trial of the new specifi

3. A randomized trial of the new specific aromatase inhibitor ‘Arimidex’ (anastrozole) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer (ABC)

✍ W. Jonat; A. Howell; C.P. Blomqvist; W. Eiermann; G. Winblad; C.J. Tyrrell; L. M 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 435 KB

A phase II study of a potent and selecti

A phase II study of a potent and selective aromatase inhibitor, anastrozole (ZD-1033), in Japanese postmenopausal women with advanced/recurrent breast cancer

✍ H. Koyama 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 147 KB

A Phase III trial comparing anastrozole

A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma

✍ Aman U. Buzdar; Stephen E. Jones; Charles L. Vogel; Janet Wolter; Paul Plourde; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

The trial was randomized, double blind for anastrozole, open label for for the Arimidex Study Group megestrol acetate, parallel group, and multicenter. Patients were randomly assigned to receive anastrozole, 1 mg (n Å 128); anastrozole, 10 mg (n Å 130); or

Survival advantage of exemestane (EXE, A

Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study

✍ E. Bajetta; L.Y. Dirix; L.E. Fein; S.E. Jones; J. Cervek; M. Kaufmann; C. Fowst; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 110 KB

Anastrozole versus megestrol acetate in

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma : Results of a survival update based on a combined analysis of data from two mature phase III trials

✍ Aman U. Buzdar; Walter Jonat; Anthony Howell; Stephen E. Jones; Carl P. Blomqvis 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

Medical University of BACKGROUND. This report presents the results of a survival update based on the combined data from two studies that compared the efficacy and tolerability of anastrozole (1 or 10 mg once daily), a selective, nonsteroidal aromatase inhibitor administered orally, and megestrol ace

Anastrozole (‘Arimidex’) versus tamoxife

Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial

✍ Beat Thürlimann; Dagmar Hess; Dieter Köberle; Isabella Senn; Pierluigi Ballabeni 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 348 KB